https://pittplusme.org/study/1545
HCC 19-059 - ICONIC Study
STUDY BASICS
Do you have a rare genitourinary (GU) tumor? If so, you may be eligible to participate in a study to help researchers test the good and bad effects of three combined cancer drugs, called cabozantinib, nivolumab, and ipilimumab, that are FDA-approved individually, but not in combination.
IRB: A031702
- Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
AGE:
18 and up
DURATION:
24 months of treatment & a follow-up period
VISITS:
Multiple
LOCATION:
UPMC Hillman Cancer Centers in Greensburg, Monroeville, Passavant & Shadyside
COMPENSATION:
NONE
SHARE STUDY
MEET THE RESEARCHER
Leonard Appleman
Leonard J. Appleman, MD, PhD, is an Associate Professor of Medicine in the Division of Hematology/Oncology. A graduate of New York University School of Medicine, Dr. Appleman’s research interests include the development of novel therapeutics for kidney cancer, prostate cancer, and other malignancies.